MRM Health presents its proprietary microbiome therapeutics optimisation and manufacturing technology at the Microbiome Movement Drug Development Conference


Ghent, Belgium - 2 February, 2021 - Microbiome specialist MRM Health presented its proprietary microbiome therapeutics technology and pipeline at the Microbiome Movement Drug Development Conference.

MRM Health NV, a biopharmaceutical company focused on the discovery and development of innovative therapeutics based on the human microbiome, outlined the proprietary technology of the company at the 5th Microbiome Movement - Drug Development Summit Europe 2021. The presentation, entitled “MRM Health – the Next Level in Optimised Consortia Development”, outlined the company’s innovative and unique approach in developing and manufacturing Optimised Synthetic Consortia as well as its pipeline. MRM Health utilises a bioinformatics-guided in-human discovery engine combined with a breakthrough in optimisation and manufacturing of consortia as single drug substance. As pioneers in consortium optimisation, MRM Health’s proprietary technology allows to develop therapeutics with faster onset-of-action, enhanced efficacy and robustness and with a cost-effective and scalable manufacturing route. This allows MRM Health’s products to have advantages compared to fecal microbiota transplantation, single strain products and conventional consortia. In addition, the company has access to unique patient cohorts in different disease areas, extensive data mining capabilities and works with leading scientific advisors across different disciplines. The most advanced drug candidate, MH002, has completed preclinical development and is in preparation for first clinical trial in patients suffering from ulcerative colitis.  MH002 has the potential to have an excellent safety profile and a differentiated Mode-of-Action from current standard-of-care, targeting multiple key mechanisms in IBD. It has shown preclinically an enhanced potency and engraftment and faster onset-of-action and robustness and is manufactured as single drug substance, as a first translation-into-practice of MRM Health’s technology platform. The pipeline of MRM Health covers a range of indications and has opportunities for further differentiation.  With a focus on inflammation, the therapeutic areas include gastrointestinal diseases, auto-immune diseases and neurological disorders. In addition, MRM Health has a therapeutic program in metabolic diseases, in strategic partnership with DuPont. “I’m delighted that I was invited to present for the first time MRM Health and our breakthrough consortia optimisation and single drug substance manufacturing technologies. MRM Health has the strong commitment of taking the development of microbiome therapeutics to the next level and delivering effective optimised microbial consortia-based therapeutics to the patient.” said Sam Possemiers, CEO and co-founder of MRM Health.

For further information:

About MRM Health

MRM Health NV, Ghent, Belgium, is a biopharmaceutical company focused on the discovery and development of innovative therapeutics based on the human microbiome. MRM Health was incorporated early 2020 by MRM Technologies, a Center of Expertise for microbiome research based in the biotech cluster in Ghent, in a joint venture with VIB, an excellence-based entrepreneurial life sciences research institute in Flanders, Belgium, that focuses on translating basic scientific results into pharmaceutical, agricultural and industrial applications.

MRM Health combines a number of proprietary innovative technologies as its discovery engine. This includes direct access to the most advanced simulator of the human gut, the Simulator of the Human Intestinal Microbial Ecosystem (SHIME®), allowing to model the complete intestine and its microbiome in the lab, in both health and disease. In addition to multiple academic and expert advisor partnerships, MRM Health also leverages, through the strategic VIB partnership, the extensive microbiome and bioinformatics capabilities of the VIB-KU Leuven lab of prof. Jeroen Raes and the multidisciplinary knowhow in inflammatory diseases and patient insights of prof. Dirk Elewaut (VIB-UGent).

To overcome critical bottlenecks currently hampering microbiome-based product development, MRM Health has developed a unique and differentiating platform for the discovery and development of novel microbiome-based therapeutics and has set up a diversified pipeline. Its most advanced program is MH002, a drug candidate for Inflammatory Bowel Disease (IBD), which includes Ulcerative Colitis (UC) and Crohn’s disease (CD). MH002 is an optimised consortium of bacteria, consisting of 6 rationally selected and well-characterised commensal strains.

MRM Health additionally has ongoing discovery programs in Spondyloarthritis, Parkinson’s Disease and specific metabolic diseases and is targeting several other medical conditions with unmet medical need. In addition to the drug candidates, its pipeline includes two advanced single strain probiotics with differentiating Mode-of-Action and advanced development status for the medical nutrition / OTC and consumer markets (PD01 and PD12).

MRM Health has a corporate collaboration with DuPont Nutrition Biosciences in the discovery and development of microbiome-based therapeutics in the field of metabolic diseases. The Company is strategically supported by strong local and international investors, including Ackermans & van Haaren, DuPont, MRM Technologies, Qbic II and VIB.